Hematology/BMT and Cellular Therapy - Academic Clinician

Benefits

Additional Information

Current Employees: If you are currently employed at any of the Universities of Wisconsin, log in to Workday to apply through the internal application process. Job Category: Academic Staff Employment Type: Regular Job Profile: Assistant Professor (CHS) Job Duties: The Department of Medicine at The University of Wisconsin and the University of Wisconsin Carbone Cancer Center (UWCCC) is recruiting an exceptional Hematologist with a focus on Bone Marrow Transplant and Cellular Therapy to join our faculty in the Division of Hematology, Medical Oncology and Palliative Care. We are looking for candidates with a track record of clinical excellence caring for patients undergoing stem cell transplantation and other cellular therapies, research focus and an interest in education as demonstrated through training and/or practice experience. An interest in clinical or translational research, with a focus in post-transplant immunological complications, use of novel cellular therapies for cancer treatment and us of bone marrow stem cells in transplant and regenerative medicine is desired. Priority areas include genomics, precision medicine and cancer therapeutics. This position is full or part time, 80%-100% This position requires work to be completed onsite, at a designated campus work location. This position has been identified as a position of trust with access to vulnerable populations. The selected candidate will be required to pass an initial caregiver check to be eligible for employment under the Wisconsin Caregiver Law and every four years. Applicants for this position will be considered for the titles: Clinical Professor, Clinical Associate Professor, Clinical Assistant Professor, Professor (CHS), Associate Professor (CHS), or Assistant Professor (CHS). The title is determined by the experience and qualifications of the finalist. Key Job Responsibilities: Clinical expectations include providing direct patient care at UW Health locations in Madison, including ambulatory, inpatient and consult service attending. This includes proactively supporting efforts to improve diversity in clinical trial participants. Academic expectations include protected time to develop and teach a research or education program and to engage in related scholarly activity. Our providers participate in clinical teaching of fellows, residents and medical students, and support the teaching and clinical research missions of the division and department. Physicians hired on the Clinical Health Sciences (CHS) track will participate in administrative and committee work to support the clinical and scholarly missions of UW Health and the School of Medicine and Public Health. An essential part of these duties will be working in a collegial relationship with other faculty members. Department: School of Medicine and Public Health / Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care The Division of Hematology, Medical Oncology and Palliative Care at UW-Madison includes more than 60 faculty, 30 Advanced Practice Providers, and 19 Fellows. The division's faculty lead cutting-edge basic, translational and clinical research programs. This research encompasses cancer biology, cancer prevention, screening and treatment, as well as survivorship and palliative care for patients impacted by solid tumors, benign and malignant hematologic conditions, and those requiring stem cell transplant or cellular therapies. Our stem cell transplant program has been FACT accredited since 2001, performing about 140-180 SCT yearly (60-70 allo-SCT yearly and 80-100 auto-SCT year) in recent years. We are a certified treatment center for all the FDA-approved commercial CART products for ALL, variety of lymphomas and multiple myeloma. Our CART patient volume had been doubling in the past 3 years, and we anticipate reaching 80-100 CART treatments per year with further growth in the coming years. In addition, we are actively participating in significant number of consortium and industry-sponsored cell therapy trials. We are conducting novel investigator-initiated therapeutic trials such as using alpha/beta T cell depleted haploidentical transplantation for the treatment of relapsed pediatric neuroblastoma and sarcomas. Our program is also developing institutional cell therapy trials including CRISPR/Cas9 generated CAR T cells for solid tumors and CNS malignancies, and ex vivo activated/expanded NK cells to treat neuroblastoma and osteogenic sarcoma, alpha/beta T cell and B cell depleted prophylactic donor lymphocyte infusion to prevent disease relapse after allo-SCT for patients with high risk of disease relapse. Additional investigator-initiated trials will be planned in collaboration with the excellent basic and translational researchers within the division, department and the institution. The University of Wisconsin has multiple well-established hematology initiatives including an endowed comprehensive sickle cell disease program, a